Eisai Co, Biogen Inc.’s Alzheimer’s drug gets EU’s marketing approval
HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.
HQ Team April 16, 2025: The 194 Member States of the WHO have reached a consensus on a draft agreement to strengthen global.
HQ Team April 15, 2025: Using artificial intelligence Stanford researchers have developed a “digital twin” of a part of a mouse brain that.
HQ Team April 15, 2025: Harvard University has rejected demands from US President Donald Trump’s administration that threaten $9 billion in research funding..
HQ Team April 15, 2025: Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of.
HQ Team April 13, 2025: A new pandemic like Covid-19 is “not a theoretical risk, it is an epidemiological certainty,” said the World.
HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.
HQ Team April 9, 2025: The United Nations has warned that “unprecedented” global aid cuts could derail a three-year trend of a 40%.
HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.
HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.